Compare GeneDx Holdings Corp (WGS) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Xpeng Inc - ADR — how do they compare? GeneDx Holdings Corp trades at $67.33 (market cap $2.02B), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: Xpeng Inc - ADR is far larger — about 4.5× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Xpeng Inc - ADR for 80 Days on average.
| WGS | XPEV | |
|---|---|---|
Market Cap | $2.02B | $9.16B |
Volume | 734,640 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $167.51 | $28.07 |
52-Week Low | $34.51 | $9.25 |
Typical Hold Time | 19 Days | 80 Days |
Enterprise Value | $2.05B | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
XPeng (XPEV) trades at $9.55, down 0.31% with bearish technical signals despite analyst optimism. The company shows strong revenue growth to $76.72B in 2025 but remains unprofitable with a -$1.14B net loss. Recent vehicle deliveries of 41,256 units in September 2026 and upcoming G9L SUV launch at Paris Motor Show highlight expansion efforts. Cash flow improved significantly with $8.26B from operations in 2025, though negative earnings surprises in Q1 and Q2 2026 raise execution concerns.
XPeng presents a high-risk growth opportunity with 58.8% analyst buy ratings and $17.55 price target suggesting 84% upside. However, persistent losses, competitive EV market pressures, and technical bearishness create significant headwinds. The stock's appeal hinges on successful Physical AI and robotics commercialization alongside sustained delivery growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
